Novonix (NVNXF) Liabilities and Shareholders Equity (2020 - 2025)

Novonix's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $282.9 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 25.13% year-over-year to $282.9 million; the TTM figure through Dec 2025 stood at $1.1 billion (up 6.49% YoY), while the FY2025 annual figure was $282.9 million, up 25.13% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $282.9 million, down from $326.9 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $326.9 million in Q2 2025, with the low at $156.2 million in Q2 2021.
• The 5-year median for Liabilities and Shareholders Equity is $279.2 million (2022), against an average of $268.9 million.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity jumped 201.81% in 2021, then slipped 14.26% in 2024.
• Novonix's Liabilities and Shareholders Equity stood at $319.7 million in 2021, then retreated by 13.23% to $277.4 million in 2022, then retreated by 5.08% to $263.3 million in 2023, then decreased by 14.14% to $226.1 million in 2024, then increased by 25.13% to $282.9 million in 2025.
• Business Quant data shows NVNXF's Liabilities and Shareholders Equity at $282.9 million in Q4 2025, $326.9 million in Q2 2025, and $226.1 million in Q4 2024.